Sepsis - Pipeline Review, H2 2018

  • ID: 4592423
  • Report
  • 278 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adrenomed AG
  • Boehringer Ingelheim GmbH
  • Cynata Therapeutics Ltd
  • Immunwork Inc
  • Opsona Therapeutics Ltd
  • SetLance srl
  • MORE
Sepsis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H2 2018, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights:

This latest pipeline guide Sepsis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 4, 2, 52, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adrenomed AG
  • Boehringer Ingelheim GmbH
  • Cynata Therapeutics Ltd
  • Immunwork Inc
  • Opsona Therapeutics Ltd
  • SetLance srl
  • MORE
Introduction

Sepsis - Overview

Sepsis - Therapeutics Development

Sepsis - Therapeutics Assessment

Sepsis - Companies Involved in Therapeutics Development

Sepsis - Drug Profiles

Sepsis - Dormant Projects

Sepsis - Discontinued Products

Sepsis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Sepsis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Sepsis - Pipeline by Adrenomed AG, H2 2018

Sepsis - Pipeline by Am-Pharma BV, H2 2018

Sepsis - Pipeline by Arch Biopartners Inc, H2 2018

Sepsis - Pipeline by Asahi Kasei Corp, H2 2018

Sepsis - Pipeline by Atox Bio Ltd, H2 2018

Sepsis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Sepsis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2018

Sepsis - Pipeline by Cells for Cells SA, H2 2018

Sepsis - Pipeline by Chiome Bioscience Inc, H2 2018

Sepsis - Pipeline by Cilian AG, H2 2018

Sepsis - Pipeline by Cynata Therapeutics Ltd, H2 2018

Sepsis - Pipeline by CytaCoat AB, H2 2018

Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H2 2018

Sepsis - Pipeline by Endacea Inc, H2 2018

Sepsis - Pipeline by Enlivex Therapeutics Ltd, H2 2018

Sepsis - Pipeline by Evec Inc, H2 2018

Sepsis - Pipeline by Expression Drug Designs LLC, H2 2018

Sepsis - Pipeline by Immunwork Inc, H2 2018

Sepsis - Pipeline by InflaRx NV, H2 2018

Sepsis - Pipeline by Integrated BioTherapeutics Inc, H2 2018

Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2018

Sepsis - Pipeline by Mochida Pharmaceutical Co Ltd, H2 2018

Sepsis - Pipeline by Nosopharm SAS, H2 2018

Sepsis - Pipeline by OncoImmune Inc, H2 2018

Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Sepsis - Pipeline by Opsona Therapeutics Ltd, H2 2018

Sepsis - Pipeline by ProThera Biologics Inc, H2 2018

Sepsis - Pipeline by Ra Pharmaceuticals Inc, H2 2018

Sepsis - Pipeline by Recce Ltd, H2 2018

Sepsis - Pipeline by Ribomic Inc, H2 2018

Sepsis - Pipeline by Rimonyx Pharmaceuticals Ltd, H2 2018

Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H2 2018

Sepsis - Pipeline by SetLance srl, H2 2018

Sepsis - Pipeline by Shionogi & Co Ltd, H2 2018

Sepsis - Pipeline by Sirtex Medical Ltd, H2 2018

Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Sepsis - Pipeline by Syntiron LLC, H2 2018

Sepsis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Sepsis - Pipeline by Therakind Ltd, H2 2018

Sepsis - Pipeline by Therashock LLC, H2 2018

Sepsis - Pipeline by TiGenix NV, H2 2018

Sepsis - Pipeline by Vascular BioSciences, H2 2018

Sepsis - Dormant Projects, H2 2018

Sepsis - Dormant Projects, H2 2018 (Contd..1), H2 2018

Sepsis - Dormant Projects, H2 2018 (Contd..2), H2 2018

Sepsis - Dormant Projects, H2 2018 (Contd..3), H2 2018

Sepsis - Dormant Projects, H2 2018 (Contd..4), H2 2018

Sepsis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Sepsis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adrenomed AG
  • Am-Pharma BV
  • Arch Biopartners Inc
  • Asahi Kasei Corp
  • Atox Bio Ltd
  • Aurigene Discovery Technologies Ltd
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cell2B Advanced Therapeutics SA
  • Cells for Cells SA
  • Chiome Bioscience Inc
  • Cilian AG
  • Cynata Therapeutics Ltd
  • CytaCoat AB
  • Dr. Franz Kohler Chemie GmbH
  • Endacea Inc
  • Enlivex Therapeutics Ltd
  • Evec Inc
  • Expression Drug Designs LLC
  • Immunwork Inc
  • InflaRx NV
  • Integrated BioTherapeutics Inc
  • Lead Discovery Center GmbH
  • Mochida Pharmaceutical Co Ltd
  • Nosopharm SAS
  • OncoImmune Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • ProThera Biologics Inc
  • Ra Pharmaceuticals Inc
  • Recce Ltd
  • Ribomic Inc
  • Rimonyx Pharmaceuticals Ltd
  • SciClone Pharmaceuticals Inc
  • SetLance srl
  • Shionogi & Co Ltd
  • Sirtex Medical Ltd
  • SK Biopharmaceuticals Co Ltd
  • Syntiron LLC
  • Takeda Pharmaceutical Co Ltd
  • Therakind Ltd
  • Therashock LLC
  • TiGenix NV
  • Vascular BioSciences
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll